Women are farmers too, says Jeremy Clarkson's new sidekick
She has given Kaleb a run for his money and now Harriet Cowan wants to be a voice for young farmers.
The 24-year-old, from Derbyshire, has become Jeremy Clarkson's new sidekick on the latest series of his popular show Clarkson's Farm, standing in for Kaleb Cooper for three episodes while he toured.
She describes herself as both a full-time farmer and nurse, working as a community nurse in Belper when she is not on the farm.
But she says her appearance in the Amazon Prime series has given her a new opportunity to speak up on farmers' mental health, be a voice for young, female farmers and attempt to change stereotypes of farming.
The programme has proved a major hit for the streaming giant since it first aired in 2021 and is now into its fourth season.
Harriet's appearances in the show have provided a further window into the mental pressures faced by the farming community.
"It's the unknown all the time," she said.
"You don't know if the grass is going to grow, you don't know how much the fertiliser is going to cost, you don't know how much you're going to sell that cow for.
"It's hard because you're in an industry where a lot of the time you work alone, and we do. It's lonely, you don't have anyone to talk to.
"I've seen a lot of farmers shut off since Covid, and they don't want to go out and socialise anymore because they're used to being isolated.
"We lost a lot of social skills. Now, it's about building them back up and getting farmers to talk again and tell people about the challenges they're facing.
"If I can do anything, I'm going to use the platform to promote the mental health aspect in farming and if I can save one life, it's something."
Listen: Harriet tells BBC Radio Derby about working with Jeremy Clarkson
Harriet says she also wants to challenge stereotypes of farming.
"I think when you talk to somebody and ask what they stereotypically think of when someone says farmer they say '60-year-old man with a checked shirt and a beer belly', and a lot of the time that is it, but us women are out here and farmers too," she said.
"Just because I'm a small, blonde that likes to curl her hair and wear make-up, it doesn't mean I can't be a farmer.
"I'm trying to change the norm of the man being the farmer and the woman being the stay-at-home wife and cook.
"When the war was on, women did all the farming, so we have always farmed - it's just changing that stereotype."
Harriet said she was approached to take part in the show by land agent Charlie Ireland – nicknamed "Cheerful Charlie" by Clarkson on the show - but admitted she had not watched a single episode before filming began.
"It worked so much better I think because I didn't know what to expect. I just went out and did what I'd do on my farm," she said.
"Every farm is slightly different but at the end of the day you all have the same goal. You're there to farm the land and look after your animals.
"Jeremy was no different. He's the same as every other farmer I know. He just wanted to achieve something with his farm and look after his animals and get the best out of it.
"Growing up, I never watched Top Gear and we don't watch a lot of TV, so he was just another farmer for me. Flat peak cap and a checked shirt.
"Genuinely, that man just wants to achieve something with his farm. He really does want to learn as well, which is the best bit for me."
Harriet says the show is truly authentic and nothing much changes when the cameras stop rolling.
"I didn't have to worry about any cameras or anything. You forgot they were even there," she said.
"We just went along, farmed and did our day-to-day stuff. Any bits that were funny were just authentically funny because that was our dynamic.
"It's nice to keep it light-hearted on a farm because it's such a serious job.
"We don't really change for the cameras coming on. We just get our heads down, farm and they do what they need to do to get the bits they need.
"There was a lot of work there with the pigs. Every day sent a new challenge. It was good fun. It was hard work but farming is hard work."
Harriet said she was pleased with the warm response to her time on the show.
"I am blown away. I can't thank people enough for how nice and positive everything's been," she said.
"I'm shocked because I didn't realise that many people were interested in me and what I do day-to-day. I've never really thought of it as anything that's exciting, it's just my little life. I get up and farm, I go to work and come back and farm.
"The way that it's blown up on social media and even walking down the street seeing people recognise us is absolutely crazy."
Harriet had a slightly frosty start to meeting Kaleb on the show but says they have become good friends since filming.
"Kaleb's amazing - me and him are so close now," she said.
"He's such a good farmer and we got on really well. He's another farmer to add to my phone list to ring.
"Everyone checks in to make sure everyone's fine. The farm is two and a bit hours away, so it's crazy to be talking to Kaleb, Jeremy, Gerald and Charlie and asking what the weather is like."
Harriet now has to decide what to do next with her new-found platform.
"My life is going to be constantly farming. I'm never not going to farm, and I know it," she said.
"I've just got to find a way to use what platform I've got to promote women in the industry and mental health.
"You're never getting me off the farm, they'll have to take me screaming and kicking."
Harriet says the door has been left open for her to potentially appear on future seasons of the show.
She said: "We've left it very open. I'm here if he needs me, but no plans at the moment."
Follow BBC Derby on Facebook, on X, or on Instagram. Send your story ideas to eastmidsnews@bbc.co.uk or via WhatsApp on 0808 100 2210.
Council denies Clarkson's claims it was 'awkward'
Show makes people aware of what farmers 'go through'
Running pub 'more stressful' than farm - Clarkson
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


UPI
34 minutes ago
- UPI
FDA OKs new COVID-19 vaccine for 65 and older, others with conditions
A vial of the Moderna COVID-19 vaccine in the Meuhedet Clinic in Jerusalem on January 3, 2022. The FDA approved a new version of the vaccine on Friday. File photo by Debbie Hill/UPI | License Photo May 31 (UPI) -- The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened vaccine standards for the virus. The FDA announced Friday that mNEXSPIKE can be given to adults 65 and older and those 12 to 64 with at least one underlying condition that could put them at risk of severe infection. Recipients also must have been previously vaccinated for COVID-19. The company, headquartered in Cambridge, Mass., said Saturday it expects to have the vaccine available for the 2025-2026 respiratory virus season. Moderna also produces Spikevax for COVID-19, and mRESVIA for the respiratory syncytial virus, or RSV. "The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19," Stéphane Bancel, chief executive officer of Moderna, said. "COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health." STAT reported the next-generation COVID-19 vaccine uses a refined target to generate antibodies against the SARS-CoV-2 virus. The dose is one-fifth the doage used in Spikevax, the current vaccine. Moderna conducted a randomized, observer-blind Phase 3 clinical trial of approximately 11,400 participants aged 12 years and older to test the mRNA-1283. The primary efficacy was to demonstrate the vaccine efficacy against COVID-19 starting 14 days after mNEXSPIKE compared with Spikevax, Moderna's updated COVID-19 vaccine approved on Sept. 6, 2024. The new vaccine showed a 9.3% higher relative vaccine efficacy than the mRNA-1273 in individuals aged 12 years and older. It was 13.5% better in adults aged 65 and older. In the Phase 3 trial, the most common side effects were injection site pain, fatigue, headache and myalgia. The company said there is a very small chance that mNEXSPIKE could cause a severe allergic reaction, usually within a few minutes to 1 hour after getting a dose of mNEXSPIKE. Myocarditis, which is inflammation of the heart muscle, and pericarditis, which is inflammation of the lining outside the heart, have occurred in some people who have received mRNA COVID-19 vaccines, Moderna said. Of those with problems, they are among males12 through 24. The FDA has asked Moderna to conduct post-marketing studies to continue to evaluate the safety and effectiveness of the product. This includes a study on the outcomes of pregnant people and their babies when the vaccine was administered during pregnancy. The study is to be submitted by the end of 2032. Pfizer was the first COVID-19 vaccine to receive emergency approval in December 2020 and Moderna was followed one week later. The first COVID-19 cases were reported in the United States in January 2020. The FDA first granted Pfizer-BioNTech full COVID-19 approval for those 12 and older in August 2021 and Moderna in January 2022. They remain available under emergency use authorization for children as young as 6 months. On Friday, the Centers for Disease Control and Prevention said children without underlying health conditions "may receive" a COVID-19 vaccine, contradicting a directive by Health and Human Services Secretary Robert F. Kennedy Jr. earlier in the week. The CDC updated the childhood immunization schedule published late Thursday. Kennedy, who said the agency would stop recommending the shots for healthy children, noted the guidelines would be changed. The new schedule also requires health insurance companies, Medicare and Medicaid plans to continue to cover the vaccines for children. COVID-19 shots during pregnancy are listed as "No Guidance/Not Applicable," where they were previously recommended for all pregnant adults. Earlier this month, the FDA approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay. The agency approved the vaccine only for people 65 and older and those 12 and older with at least one underlying condition at a higher risk of severe illness. This week, HHS notified Moderna that it was canceling contracts worth $766 million to develop, test and license vaccines for flu subtypes that could trigger future pandemics, including the dangerous H5N1 bird flu virus. The first COVID-19 case was reported in the United States on Jan. 20, 2020. About 23% of U.S. adults are estimated to be up to date with the vaccine, according to the CDC through April. For children 6 months and up to 18, it is an estimated 13.%, the CDC reported.

an hour ago
FDA approves Moderna's new lower-dose COVID-19 vaccine
The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company's existing shot, but a second option. The new vaccine, mNexspike, is a step toward next-generation coronavirus vaccines. It's made in a way that allows for a lower dose — a fifth of the dose of its current COVID-19 vaccine, Spikevax — by refining its immune target. The approval 'adds an important new tool to help protect people at high risk of severe disease from COVID-19,' Stephane Bancel, Moderna's CEO, said in a statement Saturday. The Food and Drug Administration approved the new vaccine for use in all adults 65 and older, and for people age 12 to 64 who have a least one health condition that puts them at increased risk from the coronavirus. That's the same limit that the FDA set in licensing another COVID-19 vaccine option from competitor Novavax. Those restrictions are a departure from how the U.S. has handled COVID-19 vaccines until now, reflecting skepticism about vaccines from Health Secretary Robert F. Kennedy Jr. and other Trump officials. Moderna's existing vaccine doesn't face those limits and has long been used for anyone ages 6 months and older. The company said it expected to offer both options this fall. The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective — and more by some measures — than the original shot, the company said. The news came just days after the Trump administration canceled funding for Moderna to develop a vaccine against potential pandemic flu viruses, including the H5N1 bird flu, despite promising early study results. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.


Chicago Tribune
an hour ago
- Chicago Tribune
FDA approves Moderna's new lower-dose COVID-19 vaccine
The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company's existing shot, but a second option. The new vaccine, mNexspike, is a step toward next-generation coronavirus vaccines. It's made in a way that allows for a lower dose — a fifth of the dose of its current COVID-19 vaccine, Spikevax — by refining its immune target. The approval 'adds an important new tool to help protect people at high risk of severe disease from COVID-19,' Stephane Bancel, Moderna's CEO, said in a statement Saturday. The Food and Drug Administration approved the new vaccine for use in all adults 65 and older, and for people age 12 to 64 who have a least one health condition that puts them at increased risk from the coronavirus. That's the same limit that the FDA set in licensing another COVID-19 vaccine option from competitor Novavax. Those restrictions are a departure from how the U.S. has handled COVID-19 vaccines until now, reflecting skepticism about vaccines from Health Secretary Robert F. Kennedy Jr. and other Trump officials. Moderna's existing vaccine doesn't face those limits and has long been used for anyone ages 6 months and older. The company said it expected to offer both options this fall. The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective — and more by some measures — than the original shot, the company said. The news came just days after the Trump administration canceled funding for Moderna to develop a vaccine against potential pandemic flu viruses, including the H5N1 bird flu, despite promising early study results.